Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial.
Guilhot F, Hughes TP, Cortes J, et al. Haematologica. 2012;97(5):731-38.
The TOPS trial evaluated clinical response and safety in CML patients treated with imatinib. The empirical therapeutic threshold here was consistent with earlier studies. Patients with an imatinib Cmin above threshold at steady state achieved faster major molecular response and higher rates of major molecular response and complete cytogenetic response than those patients with the lowest imatinib levels (1st quartile).